When Covid-19 hit, Gilead Sciences Inc. had enough of its experimental drug remdesivir ready to test and start manufacturing it at a larger scale. That's because it had started stockpiling not just the drug, but its ingredients, at the first hint there may be a new coronavirus. Robert Langreth reports on why the company was able to act early to prepare for a pandemic when so many businesses and institutions did not.

<p>When Covid-19 hit, Gilead Sciences Inc. had enough of its experimental drug remdesivir ready to test and start manufacturing it at a larger scale. That's because it had started stockpiling not just the drug, but its ingredients, at the first hint there may be a new coronavirus. Robert Langreth reports on why the company was able to act early to prepare for a pandemic when so many businesses and institutions did not.</p>

For much of human history, we’ve turned to diets to lose weight and improve our health. But it’s mostly been in vain. No matter how much the number on the scale drops begins to go down, chances are that the weight will come back. That’s just what the science says. But when it comes to weight, the facts just don’t seem to matter. Losing It, a new series from Bloomberg’s Prognosis, looks at how we got weight loss so wrong — and whether there’s a better way forward.

<p>For much of human history, we’ve turned to diets to lose weight and improve our health. But it’s mostly been in vain. No matter how much the number on the scale drops begins to go down, chances are that the weight will come back. That’s just what the science says. But when it comes to weight, the facts just don’t seem to matter. Losing It, a new series from Bloomberg’s Prognosis, looks at how we got weight loss so wrong — and whether there’s a better way forward.</p>

Prognosis: Losing it

Prognosis: Losing It

This Drug Maker Saw the Pandemic Coming

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/87200cb6-3363-455d-b24b-ae3900971d73/transcript

Advertisement